ProCE Banner Activity

Alliance A021602/CABINET: Phase III Trial Evaluating Cabozantinib vs Placebo for Advanced Neuroendocrine Tumors After Disease Progression on 1 or More Therapies

Conference Coverage

Results from the phase III Alliance A021602/CABINET trial showed a progression-free survival benefit with cabozantinib vs placebo for advanced neuroendocrine tumors progressing on prior therapy.

Released: October 27, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc